NEW YORK (TheStreet) -- TheStreet's Jim Cramer says Herb Greenberg knows Valeant Pharmaceuticals (VRX - Get Report) better than anyone, and he has convinced Cramer that the Canadian company's problem is it must make deal after deal to keep its roll up going.
Cramer says it is interesting to see Allergan (AGN - Get Report) drop substantially for the first time, which tells him that the deal with Valeant may not be cut and dried yet. Valeant's sale of the rights some of the key drugs it acquired in its takeover of Medicis Pharmaceuticals to Nestle all hinge on this deal with Allergan. He reminds investors that Valeant only bought Medicis a few years ago.
Cramer says he is intrigued enough to sell Allergan.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts